



Nov 21, 2020

Version 2

PBMC- 04 - In vitro Culture of TEFF+TREG - Proliferation of TEFF V.2

DOI

dx.doi.org/10.17504/protocols.io.bpxvmpn6

Marco Cosentino¹, Elisa Storelli¹, Alessandra Luini¹, Massimiliano LM Legnaro¹, Emanuela Rasini¹, Marco Ferrari¹, Franca Marino¹

¹Center for Research in Medical Pharmacology, University of Insubria (Varese, Italy)



Farmacologia Medica

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.bpxvmpn6>

Protocol Citation: Marco Cosentino, Elisa Storelli, Alessandra Luini, Massimiliano LM Legnaro, Emanuela Rasini, Marco Ferrari, Franca Marino 2020. PBMC- 04 - In vitro Culture of TEFF+TREG - Proliferation of TEFF. **protocols.io**

<https://dx.doi.org/10.17504/protocols.io.bpxvmpn6> Version created by **Farmacologia Medica**

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: November 21, 2020

Last Modified: November 21, 2020

Protocol Integer ID: 44757

Keywords: treg in drug, parkinson, proliferation of teff list, treg, journal of neuroinflammation, neuroinflammation

Abstract

List of published work using this procedure:

- Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., Sturchio, A., Mauri, M., Bono, G., Marino, F., & Cosentino, M. (2018). Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4⁺ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. *Journal of neuroinflammation*, 15(1), 205.
<https://doi.org/10.1186/s12974-018-1248-8>

Guidelines

Work under laminar flow hood when you are processing samples, from the beginning to the end of the following procedure.

Materials

MATERIALS

⊗ Fetal Bovine Serum (FBS) **EuroClone Catalog #ECS0180L-500 ml**

⊗ RPMI 1640 **EuroClone Catalog #ECM 0495L- 500 ml**

⊗ Penicillin/Streptomycin **EuroClone Catalog #ECB3001D - 100 ml**

⊗ CPD-eFluor670 - 500 µg **eBioscience Catalog #65 0840 85**

⊗ L-Glutamine 100X - 100mL **EuroClone Catalog #ECB3000D**

⊗ M-Phytohaemagglutinin powder **Merck MilliporeSigma (Sigma-Aldrich) Catalog #L8902-25 mg**

⊗ Human Interleukin 2 lyophilized powder research grade **Miltenyi Biotec Catalog #130-097-742**

Instrumentation needed:

Sterile plastic disposables

Laminar Flow Hood

Humidified 37°C, 5% CO₂ incubator

Troubleshooting



- 1 **Isolate TEFF and TREG** with Miltenyi Kit according to the **protocol PBMC- 03**.
- 2 **Count** both **TEFF** and **TREG** following the appropriate protocol (**CELL COUNT- 02**, or **CELL COUNT- 03**). Leave TREG cells in their **SOLUTION- 13** and proceed with TEFF cells.

Document

NAME

SOLUTION- 13 - Complete culture medium

CREATED BY

Farmacologia Medica

Preview

- 3 **Stain TEFF with CPD** according to the appropriate protocol.

Note

IMPORTANT!

It is necessary to have an initial number of **TEFF** of **at least 1×10^6 for staining**.

Include in your experiment also **TEFF cells unlabeled with CPD**, as fluorescent background control for FACS analysis (see the appropriate protocol in flow cytometry).

- 4 Use sterile **96-well round bottom plates**.

Note

These plates can contain a volume of maximum 250µL

- 5 Centrifuge TEFF and TREG at  1200 x g, Room temperature, 00:05:00



Equipment

Allegra AVANTI 30

NAME

Centrifuge

TYPE

Beckman Coulter

BRAND

Beckman Italy

SKU

- 6 Resuspend **TEFF** (CPD stained and unstained) and **TREG** in **SOLUTION- 13** at a **concentration of 1×10^6 /mL**.

Document

NAME

SOLUTION- 13 - Complete culture medium


CREATED BY

Farmacologia Medica

Preview

- 7 According to the experimental design, **activate** a desired number of wells containing **TEFF cells** (CPD stained and unstained) with **PHA $5 \mu\text{g/ml}$** (final concentration) and **IL-2 40 ng/mL** (final concentration) by diluting the stock aliquots. Leave also wells of **TEFF** (CPD stained and unstained) **unstimulated** (resting control).
- 8 Put **TEFF-CPD labeled cells** and **TREG cells** in the 96-well plate at a **ratio of 1:1** (for example, 0.1×10^6 TEFF + 0.1×10^6 TREG) and activate the cells in the well directly (see step 7 for concentrations): include **1 control co-culture** (not treated with test substance) and **treated co-cultures** (+test substance) according to your experimental design.



- 9 Include also a culture of **resting** and **activated TEFF alone stained and unstained CPD** (for example 0.2×10^6 cells per well), as control for the subsequent flow cytometric analysis.
- 10 Put the plate in a 37°C incubator for 120 hours.
- 11 At the end of cell culture, collect the cells in BD tubes and centrifuge them at  1200 x g, Room temperature, 00:05:00

Equipment

Allegra AVANTI 30	NAME
Centrifuge	TYPE
Beckman Coulter	BRAND
Beckman Italy	SKU

- 12 Proceed with the FACS protocol for TEFF+TREG proliferation.